On May 21, 2020 MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, reported it will host a conference call and audio webcast on Friday, May 29 at 4:30 p.m. ET (Press release, MacroGenics, MAY 21, 2020, http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-host-conference-call-and-webcast-review-preliminary [SID1234558390]). MacroGenics management will be joined by external guest presenters to review the preliminary clinical results from the ongoing Phase 1 studies of MGD013 and MGC018 that are part of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) ASCO (Free ASCO Whitepaper)20 Virtual Scientific Program.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
To participate in the MacroGenics ASCO (Free ASCO Whitepaper) 2020 Conference Call, please dial (833) 651-1036 (domestic) or (918) 922-6233 (international) ten minutes prior to the start of the call and provide the Conference ID: 7765546. The listen-only audio and slide webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company’s website at View Source A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days.
Selected Presentations at ASCO (Free ASCO Whitepaper) to be Reviewed on Conference Call
A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms (Abstract #3004)
Preliminary dose escalation results from a phase I/II, first-in-human study of MGC018 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumors (Abstract #3071, Poster #135)
About MGD013
MGD013 is an investigational, first-in-class bispecific, tetravalent DART molecule targeting PD-1 and LAG-3. MGD013 has been engineered to concomitantly or independently bind to PD-1 and LAG-3 and disrupt these non-redundant inhibitory pathways to further restore exhausted T-cell function. MGD013 is being evaluated in a Phase 1 dose expansion study as monotherapy in several tumor types, including both solid tumors and hematological malignancies, and in combination with margetuximab, an investigational Fc-engineered monoclonal antibody targeting HER-2, in a cohort of patients with advanced HER2-positive cancers (NCT03219268). MGD013 will also be evaluated in combination with margetuximab and chemotherapy as part of the ongoing Phase 2/3 MAHOGANY study in patients with HER2-positive gastric or gastroesophageal junction cancer (NCT04082364). MacroGenics’ regional partner in Greater China, Zai Lab, plans to participate in MAHOGANY and is also evaluating MGD013 independently in Phase 1 combination studies with niraparib, a PARP inhibitor, and brivanib, a dual target tyrosine kinase inhibitor of the VEGF and FGF receptors, for the study of advanced gastric cancer and hepatocellular carcinoma, respectively.
About MGC018
MGC018 is an investigational antibody-drug conjugate (ADC) that is designed to target solid tumors expressing B7-H3, a protein in the B7 family of immune regulator proteins. B7-H3 is widely expressed on many different solid tumor types, with limited expression on normal tissues. Over-expression of B7-H3 is associated with disease severity, risk of recurrence, and reduced survival. MGC018 uses a synthetic duocarmycin-based payload with a cleavable peptide linker that was licensed from Byondis (formerly Synthon Biopharmaceuticals). Duocarmycins are potent cell cycle independent DNA-damaging alkylating agents and are not subject to multi-drug resistance. MGC018 is being evaluated in a Phase 1 dose escalation study in patients with advanced solid tumors (NCT03729596).